New Insights from BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has recently made noteworthy advancements in the treatment of hereditary angioedema (HAE) by presenting new findings from the APeX-N trial. These findings were shared at the 7th Bradykinin Symposium, highlighting the vital collaboration between healthcare providers and HAE patients, which is essential for enhancing patient outcomes.
APeX-N Trial Findings
The APeX-N trial is a multi-center observational study conducted across various European countries, aimed at assessing the safety and overall quality of life for patients receiving treatment with berotralstat. In this interim analysis, which included 56 patients from the United Kingdom, France, Germany, and Sweden, significant results were noted. Approximately 12.5% of participants reported non-serious gastrointestinal issues, underscoring the necessity of monitoring side effects during treatment.
Patient Response and Adherence
Out of the participants, four patients discontinued their treatment, mainly due to less than satisfactory responses. However, one patient who suffered a severe HAE attack chose to continue with the treatment. Dr. Sorena Kiani, a prominent immunologist, remarked that the findings from the APeX-N trial align well with previously documented clinical and real-world evidence, reinforcing berotralstat's position as a leading oral prophylactic treatment for HAE.
Shared Decision-Making in Treatment
A significant aspect of one presentation at the symposium focused on the relationship between healthcare providers and patients. A dedicated study conducted in Germany explored the shared decision-making process (SDM) between healthcare providers (HCPs) and HAE patients. This study revealed several barriers that hinder effective communication and collaboration when it comes to making treatment decisions.
Barriers and Recommendations
Through structured interviews and focus group discussions with HCPs and HAE patients, the necessity for greater HCP awareness of patient experiences was highlighted. The findings suggest that placing a stronger emphasis on comprehensive education regarding HAE management could greatly enhance treatment outcomes and improve the quality of life for patients.
About ORLADEYO
ORLADEYO® (berotralstat) is the only oral therapy specifically designed to prevent HAE attacks, suitable for both adults and pediatric patients aged 12 and older. Taking just one capsule each day is crucial for reducing the frequency of attacks by inhibiting the activity of plasma kallikrein.
Safety Information and Use
While ORLADEYO is intended for long-term prophylaxis against HAE attacks, its effectiveness in treating acute HAE episodes has not yet been established. The recommended dosage should not exceed 150 mg daily to mitigate risks of QT prolongation. Patients with moderate to severe hepatic impairment may need a reduced dosage for optimal safety.
Connect with BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is committed to advancing treatment options for rare diseases through innovative research and development. With a strong focus on patient care and an impressive pipeline of therapeutic options, BioCryst is paving the way for the future of HAE treatment. For further information, individuals can reach out via email or visit their company website.
Frequently Asked Questions
What is the primary indication for ORLADEYO?
ORLADEYO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.
What were the key findings of the APeX-N trial?
The APeX-N trial reported a 12.5% occurrence of non-serious gastrointestinal events among participants, reinforcing berotralstat's effectiveness as an oral prophylactic treatment.
How does shared decision-making benefit HAE patients?
Shared decision-making improves communication between healthcare providers and patients, leading to better treatment adherence and enhanced patient quality of life.
What are the recommended dosages for ORLADEYO?
The recommended dosage for ORLADEYO is 150 mg once daily. Adjustments may be necessary for patients with significant hepatic impairment.
How can patients report adverse reactions to ORLADEYO?
Patients can report suspected adverse reactions by contacting BioCryst Pharmaceuticals or visiting the FDA's MedWatch website.
